Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 2/20 | 0.54 |
| ▸ | CDK4 | P11802 | 5/20 | 0.54 |
| ▸ | CCND1 | P24385 | 5/20 | 0.54 |
| ▸ | CCND2 | P30279 | 5/20 | 0.54 |
| ▸ | CCND3 | P30281 | 5/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.52 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 6/20 | 0.49 |
| ▸ | BRD4 | O60885 | 5/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9988749 | 0.89 | WEE1 (0.59) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL15035632 | 0.89 | WEE1 (0.54) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL15041336 | 0.89 | CDK4 (0.59) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL15036205 | 0.89 | WEE1 (0.52) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL15035629 | 0.87 | WEE1 (0.57) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL15035634 | 0.87 | WEE1 (0.65) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL15041372 | 0.87 | WEE1 (0.57) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL9988045 | 0.87 | CDK4 (0.70) | CDK4CCND1CCND2CCND3PAK4 | |
| SCHEMBL15035635 | 0.87 | WEE1 (0.56) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL659714 | 0.84 | CDK4 (0.72) | WEE1CDK4CCND1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2582374-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Afraxis, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2580216-A2 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | Afraxis, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011159945-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011156780-A2 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | WEE1 983/4885CDK4 441/4885CCND1 4422/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | WEE1 3932/4885CDK4 2822/4885CCND1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.